'Cabo' on Time for Exelixis, Fares Well; Wider Label Next?
By Randy Osborne
Friday, November 30, 2012
As expected, Exelixis Inc. won the FDA's nod for cabozantinib, a therapy for medullary thyroid cancer (MTC) a less common form of the disease, originating in parafollicular C cells but bigger revenue potential lies ahead, if the compound passes muster in metastatic prostate cancer, where Phase III trials are under way.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.